Biotech · Public company · New York, NY, US
Protara Therapeutics, Inc.
Ticker TARA · SEC CIK 0001359931
Track this companyFree. Adds Protara Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials74 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- Choline Chloride for InjectionPhase 3 · Choline DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's Choice of Intravesical ChemotherapyPhase 3 · Bladder (Urothelial, Transitional Cell) CancerClinicalTrials.gov · fetched Nov 12, 2026
- TARA-002Phase 3 · Bladder (Urothelial, Transitional Cell) CancerClinicalTrials.gov · fetched Nov 12, 2026
- TARA-002Phase 2 · Lymphatic MalformationClinicalTrials.gov · fetched Nov 12, 2026
- TARA-002Phase 2 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerPHASE3 · RECRUITING · started May 29, 2026ClinicalTrials.gov NCT07480356 · fetched Nov 12, 2026
- Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral SupportPHASE2_PHASE3 · RECRUITING · started Dec 10, 2025ClinicalTrials.gov NCT06910943 · fetched Nov 12, 2026
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgePHASE2 · RECRUITING · started Oct 18, 2023ClinicalTrials.gov NCT05871970 · fetched Nov 12, 2026
- Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerPHASE2 · RECRUITING · started Sep 15, 2023ClinicalTrials.gov NCT05951179 · fetched Nov 12, 2026
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)PHASE1 · COMPLETED · started May 8, 2023ClinicalTrials.gov NCT05085990 · fetched Nov 12, 2026
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)PHASE1 · COMPLETED · started Mar 10, 2022ClinicalTrials.gov NCT05085977 · fetched Nov 12, 2026
- Prevalence of Liver Disease in Patients Dependent on Parenteral NutritionCOMPLETED · started Aug 23, 2021ClinicalTrials.gov NCT05011370 · fetched Nov 12, 2026
SEC filings12
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · ANNUAL REPORTSEC EDGAR · filed Mar 10, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Mar 10, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026